#acurx pharmaceuticals

[cdifffoundation]

Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections

Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections

Acurx Pharmaceuticals, Inc.  a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021: Title: An Open-label Phase 2a study…

View On WordPress

[cdifffoundation]

Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections

Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections

The Antimicrobials Working Group (AWG) announced August 5, 2021 the addition of Acurx Pharmaceuticals, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for…

View On WordPress

[cdifffoundation]

Acurx Pharmaceuticals Phase 2 Clinical Trial of ibezapolstat Is In Progress

Acurx Pharmaceuticals Phase 2 Clinical Trial of ibezapolstat Is In Progress

Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced on July 27th, 2020 that a Phase 2 clinical trial of the Company’s lead antibiotic product candidate is in progress. In this trial, orally-administered ibezapolstat given 450 mg twice daily for 10 days…

View On WordPress

[cdifffoundation]

U.S. Food and Drug Administration (FDA) Grants Fast Track Status to Acurx Pharmaceuticals for New Investigational Antibiotic for Clostridium difficile Infection

U.S. Food and Drug Administration (FDA) Grants Fast Track Status to Acurx Pharmaceuticals for New Investigational Antibiotic for Clostridium difficile Infection

FDA grants Fast Track status to new C difficile antibiotic

The US Food and Drug Administration (FDA) has granted Fast Track designation to a new investigational antibiotic for Clostridioides difficile infection (CDI), according to a press release yesterday from Acurx Pharmaceuticals.

ACX-362Eis a novel, narrow-spectrum oral antibiotic based on inhibition of the enzyme DNA polymerase IIIC, which…

View On WordPress